New estrogen-free oral hormonal contraceptive (Estrogene free ill-EFP)

Czech version

Authors: P. Křepelka
Authors‘ workplace: Katedra gynekologie a porodnictví IPVZ, Praha, vedoucí pracoviště doc. MUDr. Jaroslav Feyereisl, CSc. ; 3. Lékařská fakulta UK, katedra gynekologie a porodnictví, Praha, vedoucí pracoviště prof. MUDr. Lukáš Rob, CSc. ; Ústav pro péči o matku a dítě, Praha, vedoucí pracoviště doc. MUDr. Jaroslav Feyereisl, CSc.
Published in: Ceska Gynekol 2020; 85(3): 222-225
Category:

Overview

Methods of hormonal contraception are an important tool in the implementation of family planning. Although the primary design of hormonal contraceptives was based on a combination of estrogenic and progestogenic components, the most important component of hormonal contraceptives is the progestin molecule responsible for the anti-gonadotropic effect leading to ovulation inhibition, increased cervical mucus viscosity and endometrial desynchronization. The combination of progestins with estrogens has improved the bleeding profile, but it has increased the risk of cardiovascular complications, particularly deep venous thrombosis and pulmonary embolism, in patients at specific risk. The development of purely progestogenic contraceptives is being conducted to eliminate these cardiovascular risks. A new hormonal contraceptive based on oral drospirenone alone at a daily dose of 4 mg administered in a 24-active tablet + 4 days hormone-free interval shows contraceptive efficacy and bleeding profile consistent with combined hormonal contraceptives and high safety profile as the risk of deep vein thrombosis and pulmonary embolism does not increase according to recent clinical studies. It appears to be a very effective alternative to combination products suitable for a wide range of users.

Keywords:

hormonal contraceptives – progestins – drospirenone – complications of hormonal contraception – bleeding profile

Sources

1. Archer, DF., Ahrendt, HJ., Drouin, D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015, 92, 5, p. 439- 44.

2. Bergendal, A., Odlind, V., Persson, I., et al. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand. 2009, 88, p. 261–266.

3. Dragoman, MV., Tepper, NK., Fu, R., et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018, 141, 3, p. 287-294.

4. Duijkers, JM., Heger-Mahn, D., Drouin, D., et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception, 2016, 93, 4, p. 303-309.

5. Elder, W., Beier, S., Pollow, K., et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003, 68, 10-13, p. 891-905.

6. Hall, KS., Trussell, J., Schwarz, EB. Progestin-only contraceptive pill use among women in the United States. Contraception. 2012, 86, 6, p. 653-658.

7. Jütte, R. Contraception A History. Cambridge: Polity, 2008, ISBN 0745632718, p. 288.

8. O´Wu, L., Robertson, S., Twadle, S. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technology Assessment, 2006, 10, 11 (Executive summary).

9. Palacios, S., Colli, E., Regidor, PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019, 98, 12, p. 1549-1557.

10. Regidor, PA., Colli, E., Schindler, AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016, 32, 9, p. 749-751.

11. Weisberg, E. Contraception, hormone replacement therapy and thrombosis. Aust Prescr 2002, 25, p. 57-9.